Physician profile
Ali M Fayed
NPI 1316931934
$1,056.20
in general payments reported to CMS, 2019-2025
16 companies · $71.29 in 2025
The $71.29 reported for 2025 was less than what a typical Internal Medicine provider received nationally (typical 2025 total: $156).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $40.01 · 2020: $22.72 · 2021: $146 · 2022: $493 · 2023: $230 · 2024: $54.39 · 2025: $71.29.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $355.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $355.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boehringer Ingelheim Pharmaceuticals, INC. | $147.39 | 2022 | |
| Novo Nordisk INC | $131.82 | 2021-2025 | Ozempic, Rybelsus |
| Genzyme Corporation | $125.00 | 2021 | |
| Novartis Pharmaceuticals Corporation | $120.50 | 2022 | |
| Lilly USA, LLC | $105.24 | 2019-2024 | Jardiance, Mounjaro |
| Amgen INC. | $88.18 | 2022-2025 | Repatha, Prolia, Evenity |
| Glaxosmithkline, LLC. | $59.62 | 2019-2025 | Trelegy Ellipta |
| Nevro Corp. | $59.44 | 2023 | Senza |
| Abbott Laboratories | $48.62 | 2022-2023 | Freestyle Libre 2 |
| Pfizer INC. | $46.83 | 2022-2024 | |
| Dexcom, INC. | $39.67 | 2022-2023 | Dexcom G6 Transmitter |
| Janssen Pharmaceuticals, INC | $22.72 | 2020 | |
| Shield Therapeutics INC | $17.39 | 2023 | Accrufer |
| Kowa Pharmaceuticals America, INC. | $15.81 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $15.14 | 2022 |
Show all 16 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mylan Specialty L.P. | $12.83 | 2023 | Yupelri |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ali Fayed listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.